muraglitazar: has glucose- and lipid-lowering activities; structure in first source; molecule composed of benzyloxazole-phenoxy-oxybenzylglycine-phenoxyl having structural analogy to PHENOXYBENZAMINE [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 206044 |
| CHEMBL ID | 186179 |
| CHEBI ID | 188851 |
| SCHEMBL ID | 676469 |
| MeSH ID | M0484138 |
| Synonym |
|---|
| 2-[(4-methoxyphenoxycarbonyl)({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid |
| ((4-methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid |
| [c14]-2-((4-methoxyphenoxy)carbonyl)acetic acid |
| 2-[(4-methoxyphenoxycarbonyl)({3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)amino]acetic acid |
| bdbm50150998 |
| muraglitazar |
| bms-298585 |
| pargluva |
| D05091 |
| 331741-94-7 |
| muraglitazar (usan/inn) |
| bms 298585 |
| n-((4-methoxyphenoxy)carbonyl)-n-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine |
| bms298585 |
| CHEMBL186179 , |
| mk0478 , |
| mk-0478 |
| bms-298585-01 |
| n-[(4-methoxyphenoxy)carbonyl]-n-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine |
| CHEBI:188851 |
| 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid |
| glycine, n-((4-methoxyphenoxy)carbonyl)-n-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)- |
| (((4-methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid |
| ccris 9258 |
| unii-w1mkm70wqi |
| muraglitazar [usan:inn] |
| w1mkm70wqi , |
| FT-0672555 |
| SCHEMBL676469 |
| cas-331741-94-7 |
| dtxsid9057719 , |
| tox21_113946 |
| dtxcid0031508 |
| NCGC00262954-01 |
| muraglitazar [inn] |
| muraglitazar [mart.] |
| [[(4-methoxyphenoxy)carbonyl][4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid |
| n-((4-methoxyphenoxy)carbonyl)-n-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)-methyl)glycine |
| muraglitazar [usan] |
| muraglitazar [who-dd] |
| muraglitazar [mi] |
| n-[[4-methoxyphenoxy)carbonyl]-n-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]phenyl]methyl]glycine |
| IRLWJILLXJGJTD-UHFFFAOYSA-N |
| AKOS030255656 |
| J-019059 |
| 2-(((4-methoxyphenoxy)carbonyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid |
| n-((4-methoxyphenoxy)carbonyl)-n-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)glycine |
| DB06510 |
| Q6937233 |
| bms 298585;pargluva |
| CS-0008241 |
| HY-17445 |
| glycine, n-[(4-methoxyphenoxy)carbonyl]-n-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- |
Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPARalpha/gamma agonist. It is in advanced clinical development for the treatment of type 2 diabetes and its associated dyslipidemia.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Muraglitazar is a dual (alpha/gamma) PPAR activator. " | ( Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K, 2009) | 2.11 |
| "Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPARalpha/gamma agonist that is in advanced clinical development for the treatment of type 2 diabetes and its associated dyslipidemia." | ( Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Cox, SL, 2005) | 2.49 |
| "Muraglitazar is an agonist at both of these receptors and has been shown to increase high-density lipoprotein cholesterol, decrease triglycerides and improve insulin sensitivity." | ( Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes? Doggrell, SA, 2006) | 2.5 |
| "Muraglitazar is an alpha/gamma-dual peroxisome proliferator-activated receptor (PPAR) agonist. " | ( Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology. Srinivas, N; Swaminathan, A; Yao, M, 2007) | 2.05 |
muraglitazar (10 mg kg(-1) for 14 days significantly reduced plasma glucose and triglycerides. In murag litazar-treated rats fed an acidified diet, urine pH was invariably < 6.5, which inhibited formation of calcium-and magnesium-containing solids.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Overall, there were no nonclinical findings that precluded the safe administration of muraglitazar to humans." | ( Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Dominick, MA; Sanderson, TP; Schilling, BE; Waites, CR, 2007) | 0.84 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetic parameters of muraglitazar, a novel dual-activator of the peroxisome proliferator-activated receptors (PPAR) alpha and gamma, were determined in mice, rats, dogs, and monkeys after intravenous and oral administration." | ( Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. Chandrasena, G; Chang, SY; Cheng, PT; Hariharan, N; Hosagrahara, VP; Humphreys, WG; Koplowitz, B, 2006) | 0.94 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the mouse, rat, and monkey the absolute oral bioavailability of muraglitazar ranged from 64 to 88%, and in the dog oral bioavailability was approximately 18%." | ( Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. Chandrasena, G; Chang, SY; Cheng, PT; Hariharan, N; Hosagrahara, VP; Humphreys, WG; Koplowitz, B, 2006) | 0.89 |
| " The regulated and sustained bioavailability of nitric oxide (NO) in the endothelium is essential to avoid the development of cardiovascular diseases such as hypertension or atherosclerosis." | ( The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases. Amoroso, R; Maccallini, C; Mollica, A, 2017) | 0.46 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Bile samples were collected for 3 to 8 h after dosing from group 2 subjects in addition to the urine and feces collection." | ( Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Aurang, C; Cheng, PT; Everett, DW; Humphreys, WG; Mosqueda-Garcia, R; Swaminathan, A; Wang, L; Wu, S; Xue, Y; Zhang, D, 2006) | 0.57 |
| "Muraglitazar, a PPARalpha/gamma dual agonist, was dosed orally to rats once daily for 13 weeks to evaluate urinary and urothelial changes of potential relevance to urinary bladder tumorigenesis." | ( Subchronic urinary bladder effects of muraglitazar in male rats. Arnold, LL; Cano, M; Cohen, SM; Dominick, MA; Mitroka, J; Sanderson, TP; Schilling, BE; Van Vleet, TR; Waites, CR; White, MR, 2007) | 2.05 |
| Class | Description |
|---|---|
| 1,3-oxazoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 7.0007 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 23.9145 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 23.9145 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 18.5217 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 19.4971 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.3048 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 15.2942 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 3.7575 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.6882 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248 |
| G | Vesicular stomatitis virus | Potency | 17.3768 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 27.5404 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 8.2537 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743227 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 5.9553 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 8.4852 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 19.9667 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 16.7855 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Interferon beta | Homo sapiens (human) | Potency | 17.3768 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 17.3768 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 16.7855 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 17.3768 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 17.3768 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 0.1867 | 0.0050 | 1.2051 | 10.0000 | AID1419241; AID241843; AID331455 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | IC50 (µMol) | 0.2200 | 0.0005 | 0.8269 | 6.3100 | AID241842; AID331454 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 0.2400 | 0.0020 | 0.4753 | 3.2000 | AID240312 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.2284 | 0.0000 | 0.9922 | 10.0000 | AID1192045; AID1507887; AID240111; AID240313; AID331457; AID371250; AID387492; AID418226; AID717061 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | EC50 (µMol) | 0.9528 | 0.0006 | 1.6074 | 10.0000 | AID1192048; AID1507885; AID240110; AID240312; AID331456; AID371249; AID387491; AID418223; AID717062 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID328269 | Drug concentration in bile duct-cannulated cynomolgus monkey bile assessed as recovery of radioactive dose at 5 mg/kg, po after 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387511 | Antihyperglycemic activity in db/db mouse assessed as increase in body weight at 3 mg/kg, po once daily after 28 days | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID391569 | Toxicity in db/db mouse assessed as weight gain at 3 mg/kg, po after 11 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID328509 | Biodistribution in orally dosed human urine assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1419241 | Competitive displacement of fluorescently labelled PPAR tracer ligand from GST-tagged human PPARgamma ligand binding domain after 1 hr in dark by TR-FRET competitive binding assay | 2018 | Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22 | PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. |
| AID328345 | Biodistribution in orally dosed human plasma assessed as O-Dealkyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328322 | Tmax in human at 10 mg, po after 72 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328338 | Bile excretion of compound in bile duct-cannulated orally dosed cynomolgus monkey within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328524 | Metabolic stability in CD1 mouse hepatocytes assessed as O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328361 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 12,17-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID306529 | Antidiabetic activity in db/db mouse assessed as changes in free fatty acid level at 10 mg/kg, po qd for 14 days | 2007 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8 | Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. |
| AID328560 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 9-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1214984 | Drug excretion in human urine at 20 mg, po measured during 0 to 168 hrs | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1 | Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. |
| AID328385 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as muraglitazar 12-carboxylic acid level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328416 | Biodistribution in orally dosed Beagle dog feces assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328510 | Biodistribution in orally dosed human feces assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328543 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328404 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328460 | Biodistribution in orally dosed human feces assessed as imide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328284 | Drug concentration in bile duct-cannulated Sprague-Dawley rat bile at 10 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328450 | Biodistribution in orally dosed human feces assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328352 | Biodistribution in orally dosed Beagle dog plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328260 | Drug concentration in bile duct-cannulated CD1 mouse feces assessed as recovery of radioactive dose at 1 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID238856 | Binding affinity for human peroxisome proliferator activated receptor alpha | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17 | Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID328421 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328406 | Biodistribution in orally dosed human plasma assessed as O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID240312 | Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17 | Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID328567 | Metabolic stability in human hepatocytes assessed as O-Dealkyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328273 | Drug concentration in human urine assessed as recovery of radioactive dose at 20 mg, po after 240 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID371250 | Agonist activity at human PPARgamma transactivation expressed in human HePG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID328519 | Metabolic stability in CD1 mouse hepatocytes assessed as 12-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387505 | Antihyperglycemic activity in db/db mouse assessed as reduction in plasma glucose level at 1 mg/kg, po once daily after 28 days relative to non-fasting control | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328354 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328351 | Biodistribution in orally dosed Beagle dog plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328366 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 8-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID316720 | Drug concentration in db/db mouse adipose at 10 mg/kg/day, po qd after 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. |
| AID328557 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 17-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID252394 | Triglycerides concentration in cell lysate of mouse fibroblast cell line (3T3L-1) incubated in the presence of 1.0 uM compound | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID306530 | Antidiabetic activity in db/db mouse assessed as changes in insulin level at 10 mg/kg, po qd for 14 days | 2007 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8 | Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. |
| AID331454 | Binding affinity at human PPARalpha by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID328388 | Biodistribution in orally dosed human plasma assessed as muraglitazar 12-carboxylic acid level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328424 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328554 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328314 | Tmax in cynomolgus monkey at 1.9 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328455 | Biodistribution in orally dosed human urine assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID244407 | Intrinsic activity against Peroxisome proliferator activated receptors at 1 uM relative to 1 uM GW-2331 for PPARalpha or rosiglitazone for PPARgamma | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328255 | Drug concentration in bile duct-cannulated Sprague-Dawley rat urine assessed as recovery of radioactive dose at 11 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328410 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-demethyl muraglitazar glucuronide level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328425 | Biodistribution in orally dosed human feces assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328398 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID252362 | Insulin concentration was measured in male db/db mouse after 10 mpk/day for 14 days | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328347 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 8-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID391561 | Antihyperglycemic effect in db/db mouse assessed as inhibition of blood glucose at 3 mg/kg, po after 4 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID328576 | Metabolic stability in human hepatocytes assessed as 17-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328303 | Half life in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328316 | AUC (0 to T) in cynomolgus monkey at 1.9 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328558 | Metabolic stability in cynomolgus monkey hepatocytes assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328365 | Biodistribution in orally dosed human plasma assessed as 12,17-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328478 | Biodistribution in orally dosed cynomolgus monkey feces assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID331455 | Binding affinity at human PPARalpha by fluorescence polarization | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID328568 | Metabolic stability in human hepatocytes assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328285 | Drug concentration in bile duct-cannulated CD1 mouse bile at 1 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328445 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328370 | Biodistribution in orally dosed human plasma assessed as 8-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328555 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 8-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328282 | Drug concentration in cynomolgus monkey urine at 1.9 mg/kg, po after 12 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328443 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328580 | Metabolic stability in human hepatocytes assessed as O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID418225 | Intrinsic activity at human PPARalpha ligand binding domain expressed in HEK293 cells at 1 uM by Gal4 transactivation assay relative to GW-2331 | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. |
| AID328505 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328426 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328469 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID331456 | Agonist activity at human PPARgamma expressed in HEK293 cells assessed as luciferase activity by GAL4 transactivation assay | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID328261 | Drug concentration in bile duct-cannulated CD1 mouse urine assessed as recovery of radioactive dose at 40 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328551 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328508 | Biodistribution in orally dosed cynomolgus monkey feces assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328533 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387503 | Antihyperglycemic activity in db/db mouse assessed as reduction in plasma glucose level at 0.1 mg/kg, po once daily after 28 days relative to non-fasting control | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328556 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 12-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328447 | Biodistribution in orally dosed Beagle dog feces assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387492 | Agonist activity at human PPARgamma expressed in african green monkey CV-1 co-transfected with GAL4 by by dual-glo luciferase reporter gene assay | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328468 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328525 | Metabolic stability in CD1 mouse hepatocytes assessed as hydroxyl-O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328477 | Biodistribution in orally dosed cynomolgus monkey urine assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328454 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328413 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328535 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID316715 | Decrease in plasma glucose level in db/db mouse at 10 mg/kg/day, po qd after 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. |
| AID387497 | Tmax in Sprague-Dawley rat at 3 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328360 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 17-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID244697 | Area under the concentration time curve from time 0 to infinity was measured in male SD mouse after 5 mg/kg intra arterial dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328458 | Biodistribution in orally dosed Beagle dog feces assessed as imide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID331457 | Agonist activity at human PPARalpha expressed in HEK293 cells assessed as luciferase activity by GAL4 transactivation assay | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID328437 | Biodistribution in orally dosed human urine assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID717062 | Agonist activity at GAL4-fused PPARalpha assessed as transcriptional activity by cell based assay | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1). |
| AID328564 | Metabolic stability in cynomolgus monkey hepatocytes assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328392 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as muraglitazar glucuronide level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID240110 | Effective concentration against human Peroxisome proliferator activated receptor alpha | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328502 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328538 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 12-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328506 | Biodistribution in orally dosed Beagle dog urine assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387509 | Antihyperglycemic activity in db/db mouse assessed as increase in body weight at 0.3 mg/kg, po once daily after 28 days | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328307 | Tmax in Beagle dog at 2 mg/kg, po after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328380 | Biodistribution in orally dosed Beagle dog plasma assessed as 17-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328326 | Half life in human at 10 mg, po after 72 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328274 | Drug concentration in human bile assessed as recovery of radioactive dose at 20 mg, po after 3 to 8 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328518 | Metabolic stability in CD1 mouse hepatocytes assessed as 8-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328295 | Fecal excretion of compound in orally dosed human within 96 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328320 | Cmax in human at 10 mg, po after 72 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328495 | Biodistribution in orally dosed cynomolgus monkey urine assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328501 | Biodistribution in orally dosed human feces assessed as acetylimide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID249195 | Time to maximum concentration was measured in male SD mouse after 10 mg/kg oral dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328515 | Metabolic stability in CD1 mouse hepatocytes assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328386 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as muraglitazar 12-carboxylic acid level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328393 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as muraglitazar glucuronide level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328283 | Drug concentration in human urine at 10 mg/kg, po after 8 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328523 | Metabolic stability in CD1 mouse hepatocytes assessed as 9-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387496 | Volume of distribution at steady state in Sprague-Dawley rat at 3 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328526 | Metabolic stability in CD1 mouse hepatocytes assessed as hydroxyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID306528 | Antidiabetic activity in db/db mouse assessed as changes in glucose level at 10 mg/kg, po qd for 14 days | 2007 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8 | Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. |
| AID328407 | Biodistribution in orally dosed human plasma assessed as O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328461 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328583 | Metabolic stability in human hepatocytes assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328451 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328456 | Biodistribution in orally dosed human feces assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328579 | Metabolic stability in human hepatocytes assessed as 9-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328494 | Biodistribution in orally dosed Beagle dog feces assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328318 | Half life in cynomolgus monkey at 1.9 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328584 | Metabolic stability in human hepatocytes assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID316716 | Decrease in plasma triglyceride level in db/db mouse at 10 mg/kg/day, po qd after 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. |
| AID328362 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12,17-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328375 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328395 | Biodistribution in orally dosed human plasma assessed as muraglitazar glucuronide level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328522 | Metabolic stability in CD1 mouse hepatocytes assessed as muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507889 | Modulation of SGK1 mRNA expression in HCCD cells at 20 uM after 24 hrs by RT-PCR method relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID252364 | Triglycerides concentration was measured in male db/db mouse after 10 mpk/day for 14 days | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328537 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 8-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328372 | Biodistribution in orally dosed Beagle dog plasma assessed as 12-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328585 | Metabolic stability in human hepatocytes assessed as di-oxygenated muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328257 | Drug concentration in bile duct-cannulated Sprague-Dawley rat feces assessed as recovery of radioactive dose at 11 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328368 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 8-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507897 | Toxicity in ob/ob mouse assessed as change in body weight at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328436 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID391563 | Antihyperglycemic effect in db/db mouse assessed as inhibition of blood glucose at 3 mg/kg, po after 11 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID328349 | Biodistribution in orally dosed human plasma assessed as 8-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID391567 | Toxicity in db/db mouse assessed as weight gain at 3 mg/kg, po after 4 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID241843 | Inhibition of human Peroxisome proliferator activated receptor gamma | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID371252 | Selectivity ratio of EC50 for human PPARgamma receptor to human PPARalpha receptor expressed in human HpG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID328465 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1192049 | Intrinsic activity at GAL4 tagged human PPARalpha ligand binding domain expressed in HEK293 cells at 1 uM by luciferase reporter gene assay relative to 1 uM GW2331 | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists. |
| AID328572 | Metabolic stability in human hepatocytes assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328254 | Drug concentration in Sprague-Dawley rat feces assessed as recovery of radioactive dose at 11 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328291 | Fecal excretion rate in orally dosed Beagle dog within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328359 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 17-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328578 | Metabolic stability in human hepatocytes assessed as muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387495 | Clearance in Sprague-Dawley rat at 3 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328561 | Metabolic stability in cynomolgus monkey hepatocytes assessed as O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328420 | Biodistribution in orally dosed human feces assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID252361 | Glucose concentration was measured in male db/db mouse after 10 mpk/day for 14 days | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID1507884 | Transactivation of human Gal4-fused PPARalpha LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay relative to WY14643 | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328389 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as muraglitazar glucuronide level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328399 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328484 | Biodistribution in orally dosed human urine assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328476 | Biodistribution in orally dosed Beagle dog feces assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328258 | Drug concentration in bile duct-cannulated CD1 mouse urine assessed as recovery of radioactive dose at 1 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328475 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328439 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328496 | Biodistribution in orally dosed cynomolgus monkey feces assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328442 | Biodistribution in orally dosed human feces assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328434 | Biodistribution in orally dosed Beagle dog feces assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328414 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328423 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328479 | Biodistribution in orally dosed human feces assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328382 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 17-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328440 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328548 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as di-oxygenated muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328507 | Biodistribution in orally dosed cynomolgus monkey urine assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328432 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328324 | AUC (0 to T) in human at 10 mg, po after 72 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328488 | Biodistribution in orally dosed Beagle dog feces assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID249211 | Half life was measured in male SD mouse after 10 mg/kg oral dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328512 | Metabolic stability in CD1 mouse hepatocytes assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328390 | Biodistribution in orally dosed Beagle dog plasma assessed as muraglitazar glucuronide level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328256 | Drug concentration in bile duct-cannulated Sprague-Dawley rat bile assessed as recovery of radioactive dose at 11 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID371249 | Agonist activity at human PPARalpha transactivation expressed in human HePG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID328305 | Cmax in Beagle dog at 2 mg/kg, po after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328545 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as hydroxyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1192048 | Agonist activity at GAL4 tagged human PPARalpha ligand binding domain expressed in HEK293 cells by luciferase reporter gene assay | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists. |
| AID328511 | Metabolic stability in CD1 mouse hepatocytes assessed as O-Dealkyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328401 | Biodistribution in orally dosed Beagle dog plasma assessed as O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328259 | Drug concentration in bile duct-cannulated CD1 mouse bile assessed as recovery of radioactive dose at 1 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328422 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328272 | Drug concentration in human feces assessed as recovery of radioactive dose at 10 mg, po after 240 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328528 | Metabolic stability in CD1 mouse hepatocytes assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328577 | Metabolic stability in human hepatocytes assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1192046 | Intrinsic activity at GAL4 tagged human PPARgamma ligand binding domain expressed in HEK293 cells at 1 uM by luciferase reporter gene assay relative to 1 uM rosiglitazone | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists. |
| AID328266 | Drug concentration in cynomolgus monkey urine assessed as recovery of radioactive dose at 2 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328500 | Biodistribution in orally dosed cynomolgus monkey feces assessed as acetylimide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328369 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 8-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328374 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328356 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328462 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328412 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-demethyl muraglitazar glucuronide level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID371251 | Agonist activity at human PPARdelta transactivation expressed in human HePG2 cells up to 1 uM | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID331459 | Intrinsic activity at human PPARalpha expressed in HEK293 cells assessed as luciferase activity at 1 uM by GAL4 transactivation assay relative to Muraglitazar | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID328542 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 9-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID240111 | Effective concentration against human Peroxisome proliferator activated receptor gamma | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328499 | Biodistribution in orally dosed Beagle dog feces assessed as acetylimide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328569 | Metabolic stability in human hepatocytes assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328492 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328444 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328565 | Metabolic stability in cynomolgus monkey hepatocytes assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387491 | Agonist activity at human PPARalpha expressed in african green monkey CV-1 by co-transfected with GAL4 by by dual-glo luciferase reporter gene assay | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328371 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 12-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328498 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as acetylimide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328265 | Drug concentration in Beagle dog feces assessed as recovery of radioactive dose at 1.9 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1214985 | Drug excretion in human bile at 20 mg, po measured during 3 to 8 hrs | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1 | Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. |
| AID328463 | Biodistribution in orally dosed Beagle dog feces assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328384 | Biodistribution in orally dosed human plasma assessed as 17-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328357 | Biodistribution in orally dosed human plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328376 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328529 | Metabolic stability in CD1 mouse hepatocytes assessed as di-oxygenated muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328552 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328457 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as imide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328446 | Biodistribution in orally dosed human feces assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328464 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328562 | Metabolic stability in cynomolgus monkey hepatocytes assessed as hydroxyl-O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387498 | Cmax in Sprague-Dawley rat at 3 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328270 | Drug concentration in bile duct-cannulated cynomolgus monkey feces assessed as recovery of radioactive dose at 5 mg/kg, po after 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387493 | Half life in Sprague-Dawley rat at 3 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID316719 | Drug concentration in db/db mouse liver at 10 mg/kg/day, po qd after 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. |
| AID328513 | Metabolic stability in CD1 mouse hepatocytes assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328417 | Biodistribution in orally dosed cynomolgus monkey urine assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328297 | Cmax in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328299 | Tmax in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328573 | Metabolic stability in human hepatocytes assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328287 | Drug concentration in human bile at 20 mg/kg, po after 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID241842 | Inhibition of human Peroxisome proliferator activated receptor alpha | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328516 | Metabolic stability in CD1 mouse hepatocytes assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328355 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328472 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328342 | Biodistribution in orally dosed Beagle dog plasma assessed as O-Dealkyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328486 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507891 | Anti-diabetic activity in ob/ob mouse assessed as change in serum triglyceride levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328348 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 8-hydroxy-O-demethyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328581 | Metabolic stability in human hepatocytes assessed as hydroxyl-O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328293 | Fecal excretion of compound in orally dosed cynomolgus monkey within 96 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328377 | Biodistribution in orally dosed human plasma assessed as 12-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328481 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID240313 | Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17 | Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID1507886 | Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay relative to rosiglitazone | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328312 | Cmax in cynomolgus monkey at 1.9 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID717061 | Agonist activity at GAL4-fused PPARgamma assessed as transcriptional activity by cell based assay | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1). |
| AID328466 | Biodistribution in orally dosed human urine assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328536 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID391568 | Toxicity in db/db mouse assessed as weight gain at 3 mg/kg, po after 7 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID328547 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328350 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328467 | Biodistribution in orally dosed human feces assessed as 12-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328400 | Biodistribution in orally dosed Beagle dog plasma assessed as O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328309 | AUC (0 to T) in Beagle dog at 2 mg/kg, po after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID418226 | Binding affinity to PPARgamma by fluorescence polarization assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. |
| AID328497 | Biodistribution in orally dosed human feces assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328563 | Metabolic stability in cynomolgus monkey hepatocytes assessed as hydroxyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328449 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328391 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as muraglitazar glucuronide level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328428 | Biodistribution in orally dosed human feces assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328409 | Biodistribution in orally dosed Beagle dog plasma assessed as O-demethyl muraglitazar glucuronide level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328286 | Drug concentration in bile duct-cannulated cynomolgus monkey bile at 5 mg/kg, po after 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328503 | Biodistribution in orally dosed cynomolgus monkey urine assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328280 | Drug concentration in Sprague-Dawley rat urine at 11 mg/kg, po after 12 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387501 | Oral bioavailability in Sprague-Dawley rat at 3 mg/kg | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328268 | Drug concentration in bile duct-cannulated cynomolgus monkey urine assessed as recovery of radioactive dose at 5 mg/kg, po after 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328408 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as O-demethyl muraglitazar glucuronide level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328470 | Biodistribution in orally dosed Beagle dog feces assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID244506 | Clearance was measured in male SD mouse after 5 mg/kg intra arterial dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328301 | AUC (0 to T) in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328541 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328262 | Drug concentration in bile duct-cannulated CD1 mouse bile assessed as recovery of radioactive dose at 40 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328275 | Drug concentration in human feces assessed as recovery of radioactive dose at 20 mg, po after 240 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328485 | Biodistribution in orally dosed human feces assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328337 | Fecal excretion of compound in bile duct-cannulated orally dosed Sprague-Dawley rat within 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328514 | Metabolic stability in CD1 mouse hepatocytes assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328341 | Biodistribution in orally dosed Beagle dog plasma assessed as O-Dealkyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328471 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328517 | Metabolic stability in CD1 mouse hepatocytes assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328379 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as 17-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507893 | Anti-diabetic activity in ob/ob mouse assessed as change in serum glucose levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328489 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328281 | Drug concentration in Beagle dog urine at 2 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328276 | Metabolic stability in CD1 mouse hepatocytes assessed as radioactivity recovaries at 25.6 ug/mL after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328571 | Metabolic stability in human hepatocytes assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328493 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID418223 | Binding affinity to PPARalpha by fluorescence polarization assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. |
| AID328340 | Biodistribution in orally dosed Beagle dog plasma assessed as O-Dealkyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID252367 | Free fatty acid concentration was measured in male db/db mouse after 10 mpk/day for 14 days | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID387510 | Antihyperglycemic activity in db/db mouse assessed as increase in body weight at 1 mg/kg, po once daily after 28 days | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328433 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328419 | Biodistribution in orally dosed human urine assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328397 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328427 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387512 | Antihyperglycemic activity in po dosed db/db mouse assessed as reduction in glucose level after 28 days | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID1468729 | Toxicity in Sprague-Dawley rat assessed as reduction in hematocrit level at 100 mg/kg for 4 weeks | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. |
| AID391562 | Antihyperglycemic effect in db/db mouse assessed as inhibition of blood glucose at 3 mg/kg, po after 7 days | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. |
| AID328448 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 12,17-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328453 | Biodistribution in orally dosed Beagle dog feces assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328387 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as muraglitazar 12-carboxylic acid level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328575 | Metabolic stability in human hepatocytes assessed as 12-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID246004 | Maximum concentration was measured in male SD mouse after 10 mg/kg oral dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328271 | Drug concentration in human urine assessed as recovery of radioactive dose at 10 mg, po after 240 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328570 | Metabolic stability in human hepatocytes assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328487 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328263 | Drug concentration in bile duct-cannulated CD1 mouse feces assessed as recovery of radioactive dose at 40 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID316718 | Drug concentration in db/db mouse plasma at 10 mg/kg/day, po qd after 14 days | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. |
| AID328329 | Fecal excretion of compound in bile duct-cannulated orally dosed cynomolgus monkey within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328574 | Metabolic stability in human hepatocytes assessed as 8-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328277 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as radioactivity recovaries at 25.6 ug/mL after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328378 | Biodistribution in orally dosed human plasma assessed as 12-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328394 | Biodistribution in orally dosed human plasma assessed as muraglitazar glucuronide level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328504 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as O-dealkyl-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328405 | Biodistribution in orally dosed human plasma assessed as O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328381 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 17-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328430 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328364 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12,17-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328490 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328521 | Metabolic stability in CD1 mouse hepatocytes assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328549 | Metabolic stability in cynomolgus monkey hepatocytes assessed as O-Dealkyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387508 | Antihyperglycemic activity in db/db mouse assessed as increase in body weight at 0.1 mg/kg, po once daily after 28 days | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328418 | Biodistribution in orally dosed cynomolgus monkey feces assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328582 | Metabolic stability in human hepatocytes assessed as hydroxyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387494 | AUC (0 to 24 hrs) in Sprague-Dawley rat at 3 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328353 | Biodistribution in orally dosed Beagle dog plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID331458 | Intrinsic activity at human PPARgamma expressed in HEK293 cells assessed as luciferase activity at 1 uM by GAL4 transactivation assay relative to Muraglitazar | 2008 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12 | Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists. |
| AID1468732 | Toxicity in Sprague-Dawley rat assessed as increase in plasma volume at 100 mg/kg for 4 weeks by evans blue dye based assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. |
| AID328367 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 8-dihydroxy muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID245830 | Volume of distribution at study state was measured in male SD mouse after 5 mg/kg intra arterial dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328383 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 17-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328288 | Fecal excretion rate in orally dosed Sprague-Dawley rat within 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328546 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328373 | Biodistribution in orally dosed Beagle dog plasma assessed as 12-dihydroxy muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328550 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328279 | Metabolic stability in human hepatocytes assessed as radioactivity recovaries at 25.6 ug/mL after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328290 | Fecal excretion rate in orally dosed Beagle dog within 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328553 | Metabolic stability in cynomolgus monkey hepatocytes assessed as 9-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328344 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-Dealkyl muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328267 | Drug concentration in cynomolgus monkey feces assessed as recovery of radioactive dose at 2 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328520 | Metabolic stability in CD1 mouse hepatocytes assessed as 17-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507895 | Anti-diabetic activity in ob/ob mouse assessed as change in serum insulin levels at 3 mg/kg administered via oral gavage daily for 4 days measured on day 5 relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID1507887 | Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328531 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 8-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328346 | Biodistribution in orally dosed human plasma assessed as O-Dealkyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328532 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387506 | Antihyperglycemic activity in db/db mouse assessed as reduction in plasma glucose level at 3 mg/kg, po once daily after 28 days relative to non-fasting control | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328452 | Biodistribution in orally dosed Sprague-Dawley rat feces assessed as 8-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328480 | Biodistribution in orally dosed Sprague-Dawley rat urine assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328289 | Fecal excretion rate in orally dosed Sprague-Dawley rat within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328441 | Biodistribution in orally dosed cynomolgus monkey feces assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328474 | Biodistribution in orally dosed human feces assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328435 | Biodistribution in orally dosed cynomolgus monkey urine assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387504 | Antihyperglycemic activity in db/db mouse assessed as reduction in plasma glucose level at 0.3 mg/kg, po once daily after 28 days relative to non-fasting control | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328534 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 17-hydroxy-O-demethyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328336 | Drug concentration in bile duct-cannulated CD1 mouse bile at 40 mg/kg, po after 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328403 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-demethyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID244696 | Area under the concentration time curve from time 0 to infinity was measured in male SD mouse after 10 mg/kg oral dosage; n=3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6 | Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and |
| AID328328 | Bile excretion of compound in bile duct-cannulated orally dosed Sprague-Dawley rat within 24 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328559 | Metabolic stability in cynomolgus monkey hepatocytes assessed as muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328358 | Biodistribution in orally dosed human plasma assessed as 12-hydroxy-O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328429 | Biodistribution in orally dosed Beagle dog feces assessed as 9,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328540 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as muraglitazar 12-carboxylic acid level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328343 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-Dealkyl muraglitazar level after 1 hr by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328530 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as O-Dealkyl muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328473 | Biodistribution in orally dosed human urine assessed as 17-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328396 | Biodistribution in orally dosed human plasma assessed as muraglitazar glucuronide level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328292 | Fecal excretion of compound in orally dosed cynomolgus monkey within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328491 | Biodistribution in orally dosed human feces assessed as 9-hydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387499 | AUC (0 to 24 hrs) in Sprague-Dawley rat at 3 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID1507888 | Activation of recombinant human SIRT1 at 10 uM using C-terminal AMC labeled Arg-His-Lys-Lys (Ac) as substrate after 30 mins by FLUOR DE LYS fluorescent assay relative to control | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID328459 | Biodistribution in orally dosed cynomolgus monkey feces assessed as imide derivative of muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328527 | Metabolic stability in CD1 mouse hepatocytes assessed as O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID238857 | Binding affinity for human peroxisome proliferator activated receptor gamma | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17 | Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID328431 | Biodistribution in orally dosed human feces assessed as 8,12-dihydroxy muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328544 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as hydroxyl-O-demethyl muraglitazar glucuronide level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID306527 | Antidiabetic activity in db/db mouse assessed as changes in triglyceride level at 10 mg/kg, po qd for 14 days | 2007 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8 | Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I. |
| AID328566 | Metabolic stability in cynomolgus monkey hepatocytes assessed as di-oxygenated muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328294 | Fecal excretion of compound in orally dosed human within 48 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328415 | Biodistribution in orally dosed Beagle dog urine assessed as O-dealkyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328402 | Biodistribution in orally dosed Beagle dog plasma assessed as O-demethyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328438 | Biodistribution in orally dosed human feces assessed as 12-hydroxy-O-demethyl muraglitazar level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID387500 | Solubility at pH 6.8 | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. |
| AID328411 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as O-demethyl muraglitazar glucuronide level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328539 | Metabolic stability in Sprague-Dawley rat hepatocytes assessed as 17-hydroxy muraglitazar level by LC/MS analysis relative to control | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1507885 | Transactivation of human Gal4-fused PPARalpha LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. |
| AID418228 | Intrinsic activity at human PPARgamma ligand binding domain expressed in HEK293 cells at 1 uM by Gal4 transactivation assay relative to rosiglitazone | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. |
| AID1468735 | Toxicity in Sprague-Dawley rat assessed as increase in heart weight at 100 mg/kg for 6 weeks | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. |
| AID328253 | Drug concentration in Sprague-Dawley rat urine assessed as recovery of radioactive dose at 11 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328482 | Biodistribution in orally dosed cynomolgus monkey urine assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328339 | Biodistribution in orally dosed Sprague-Dawley rat plasma assessed as O-Dealkyl muraglitazar level after 12 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328264 | Drug concentration in Beagle dog urine assessed as recovery of radioactive dose at 1.9 mg/kg, po after 168 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328483 | Biodistribution in orally dosed cynomolgus monkey feces assessed as muraglitazar glucuronide level by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1192045 | Agonist activity at GAL4 tagged human PPARgamma ligand binding domain expressed in HEK293 cells by luciferase reporter gene assay | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists. |
| AID328278 | Metabolic stability in cynomolgus monkey hepatocytes assessed as radioactivity recovaries at 25.6 ug/mL after 4 hrs | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID328363 | Biodistribution in orally dosed cynomolgus monkey plasma assessed as 12,17-dihydroxy muraglitazar level after 4 hrs by LC/MS analysis | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 35, Issue:1 | Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 59 (69.41) | 29.6817 |
| 2010's | 18 (21.18) | 24.3611 |
| 2020's | 8 (9.41) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (11.76%) | 5.53% |
| Reviews | 11 (12.94%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 64 (75.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||